How to pick a theme for an investment newsletter

Written by: Zack Miller | December 8, 2008

As submitted by The New Rules of Investing:

What do you think of when I mention “investment newsletter”?

magnifying_glass

Many will answer referencing the numerous emails (spam?) they receive on a daily basis with information “that’s guaranteed to triple your money!” While that’s a preposterous boast, I think the most important thing to do when starting a financial newsletter business is picking the theme of the newsletter.

Picking a niche topic versus building a general investment newsletter

The key in the investment newsletter business is positioning (see this for an explanation about your Unique Selling Proposition), just like in many other consumer-focused businesses. Success in branding, marketing and distributing your newsletter will be built upon your investment newsletter’s theme. e-books, like newsletters, follow similar rules.

So, is it better to go niche with your newsletter (and publish the clean technology newsletter) or stay broad with a loosely-defined universe (like Joe’s Top Stock Picks)?

I think there is a fine balance between being to tightly-defined (Chuck’s Tech Stocks that Begin with the Letter ‘A’) and standing out from the rest of the pack.

See what else is out there

Go to Forbes Newsletter site.  Forbes runs a whole business where they distribute and market other people’s newsletters.  Check out some of the leading titles.  You’ve got

The majority of the investment newsletters tend to fall in the broad category.  This is probably because the audience served by a broad newsletter is larger than any of the other options.  If you choose to go this route, you fall into the space with the greatest noise.

Buck the trend

The reason so many newsletters have to resort to such slimy marketing tactics is because they lack differentiation because they are so broad.  If you want to stay above the fray, get better defined, without becoming so niche that you become irrelevant.

Have the foresight to scout future trends.  Analyze new investment products as they gain traction.  Scout new geographies where visibility is poor (China hasn’t been taken seriously enough).  Have the insight to pick an investment newsletter focused on the next hot sector in technology.  There will always be buyers (albeit, fewer) for more niche newsletters.

But here’s the thing: they’ll pay more for your expertise.  So instead of finding yourself in the $39-$149/year club, you’ll push the upper range.

 

Israel Stocks in the U.S. (by market cap)

Written by: Israel Investor Newsletter | July 20, 2008

Israel Stocks Trading in the U.S.

UPDATED 7/2008

Top 30 Israeli Stocks in the U.S. by Market Cap

Teva Pharmaceutical Industries Ltd (TEVA)
Marvell Technology Group Ltd. (MRVL)
Amdocs Limited (DOX)
Check Point Software Technologies Ltd. (CHKP)
Partner Communications Company Ltd (PTNR)
Perrigo Company (PRGO)
NDS Group plc (NNDS)
Cellcom Israel Ltd. (CEL)
Africa Israel Invts Ltd (AFIVY.PK)
Comverse Technology Inc. (CMVT.PK)
Elbit Systems Ltd. (ESLT)
Ormat Technologies, Inc. (ORA)
Nice Systems Ltd. (NICE)
Equity One, Inc. (EQY)
Savient Pharmaceuticals, Inc. (SVNT)
Verifone (PAY)
Elbit Medical Imaging Ltd (EMITF)
Electronics for Imaging, Inc. (EFII)
Verint Systems Inc. (VRNT.PK)
Zoran Corporation (ZRAN)
Blue Square Israel Ltd. (BSI)
Mellanox Technologies, Ltd (MLNX)
Given Imaging Ltd. (GIVN)
Gilat Satellite Networks Ltd (GILT)
Alon USA Energy, Inc. (ALJ)
Alvarion Ltd. (ALVR)
Delek US Holdings, Inc. (DK)
Ness Technologies, Inc (NSTC)
Syneron Medical Ltd. (ELOS)

For a full list of all Israeli firms traded in the U.S., click here.

 

Israel ETF Update 7/10/2008

Written by: Israel Investor Newsletter | July 10, 2008

June was a tough month for the market in general and Israel stocks were hit with a double whammy: tech stocks proved they were no longer immune to the weakening economy and the shekel continued its march higher versus the dollar.

Both EIS, the iShares MSCI Israel Capped Investable Market Index Fund, and the TAV, the NETS TA-25 Index Fund, were down about 3-4% with the overall Nasdaq down about 8%.

If you look closer at the chart, you’ll see that the TAV just recently outperformed the EIS.  TEVA Pharmaceuticals (TEVA) was recently hit hard off of news of more imminent generic competition to Teva’s Copaxone (tables turned, eh?) in spite of some incrementally positive news on progress on a drug to treat Parkinsons.

We’ve written about the EIS’s extreme exposure to the generic pharma giant (weighing in at almost 25% of EIS) and this in turn, makes iShares’ Israel ETF more susceptible to fluctuations in TEVA’s stock price and ultimately, not as good a proxy for the entire Israeli market (of which TEVA constitutes less than 10% of market cap and which the TAV attempts to mimic).

Some additional reading:

 

Investor Insight: Dave Fry, ETF Digest

Written by: Zack Miller | June 25, 2008

The entire interview with Dave Fry of ETF Digest part of our new subscription newsletter, Israel Opportunity Investor. You can find out more about the product and the opportunities we cover at www.israelnewsletter.com.

*****************************************************

How did you become a leading analyst on ETFs?
Dave Fry, Founder of ETF Digest: I think being early in coverage of these fast growing investment vehicles is the easy answer.  Beyond that we have tried to be more honest and blunt in our coverage of new products.  We haven’t been “yes men” or suck ups for issuers and sponsors for example.  Where we’ve been critical some ETF sponsors won’t talk to us any more for example which isn’t a bother since we don’t use their products anyway.  Further where there are problems we’ve been out front in pointing these out.  That occurred with shorting problems for retail investors where the promised benefit didn’t meet reality. (Continue »)

 

 Page 1 of 3  1  2  3 »